Fresenius launches denosumab biosimilars in EU

Fresenius announced the launch of its denosumab biosimilars, Conexxence (denosumab) and Bomyntra (denosumab), in Europe.

These biosimilars received approval from the European Commission in July 2025 for all indications of the reference products Prolia (denosumab) and Xgeva (denosumab), respectively.

“Being the first biosimilar company with a pre-filled syringe for the denosumab oncology indication in Europe, showcases our commitment to offering new treatment options that support patient care and affordability across Europe,” said Dr. Sang Jin Pak, President Biopharma., Fresenius Kabi.